Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in mCRPC
NCT02913196Phase 1Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Dec 2016
- Primary completion
- Jun 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of apalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Weill Cornell Medicine. Primary endpoint: Dose Limiting Toxicities at 36 months. Started Dec 2016; status: completed.
02
Drugs
apalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02913196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02913196.